In this edition, DNA sequencing could identify patients with high-risk AML; review of major advances and challenges in chronic lymphocytic leukemia; FDA advisory panel backs polatuzumab vedotin and more.
Read the full coverage here:
DNA sequencing could identify patients with AML at high risk for relapse after HSCT
Review highlights major advances, continuing challenges in chronic lymphocytic leukemia
FDA advisory panel backs polatuzumab vedotin-piiq benefit-risk profile in first-line DLBCL
CAR T cells improve quality of life for majority of recipients
Community physicians play essential role in long-term care after CAR-T
References:
Dillon LW, et al. JAMA. 2023;doi:10.1001/jama.2023.1363.
Healio Interviews
Johnson PC, et al. Blood Adv. 2023;doi:10.1182/bloodadvances.2022009117.
